Biblio
Export 1352 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is P [Clear All Filters]
“Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
, “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
, “Cardiorespiratory Fitness and Cognitive Function are Positively Related Among Participants with Mild and Subjective Cognitive Impairment.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1865-1875, 2018.
, “Cardiorespiratory Fitness Attenuates the Deleterious Effects of Sleep Apnea on Cerebral Structure and Perfusion in the Wisconsin Sleep Cohort Study.”, J Alzheimers Dis, vol. 95, no. 2, pp. 427-435, 2023.
, “Cardiorespiratory Fitness Attenuates the Deleterious Effects of Sleep Apnea on Cerebral Structure and Perfusion in the Wisconsin Sleep Cohort Study.”, J Alzheimers Dis, vol. 95, no. 2, pp. 427-435, 2023.
, “Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1045-1052, 2022.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “CD44 Splice Variants as Potential Players in Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1137-1149, 2017.
, “Central Obesity, Cardiometabolic Risk, and Cognitive Change in the Study of Latinos: Investigation of Neurocognitive Aging.”, J Alzheimers Dis, vol. 82, no. 3, pp. 1203-1218, 2021.
, “Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.
, “Cerebral Amyloid Angiopathy and Neuritic Plaque Pathology Correlate with Cognitive Decline in Elderly Non-Demented Individuals.”, J Alzheimers Dis, vol. 67, no. 1, pp. 411-422, 2019.
, “Cerebral Hemodynamics in Mild Cognitive Impairment: A Systematic Review.”, J Alzheimers Dis, vol. 59, no. 1, pp. 369-385, 2017.
, “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.
, “Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 1, pp. 183-200, 2017.
, “Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 1, pp. 183-200, 2017.
, “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
, “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
, “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
, “Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.”, J Alzheimers Dis, vol. 55, no. 2, pp. 625-644, 2017.
, “Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment.”, J Alzheimers Dis, vol. 64, no. s1, pp. S281-S287, 2018.
, “Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.”, J Alzheimers Dis, vol. 66, no. 2, pp. 551-563, 2018.
, “Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.”, J Alzheimers Dis, vol. 66, no. 2, pp. 551-563, 2018.
,